The difference between sotorasib targeted therapy and chemotherapy

As a targeted drug, Sotorasib is significantly different from traditional chemotherapy in terms of mechanism of action, therapeutic effect, and side effects. This difference makes it more personalized and targeted when treating patients with specific types of lung cancer.

1. Differences in mechanism of action

Targeted therapy: Sotoraxib is a targeted inhibitor of the KRAS G12C mutation, which specifically targets the KRAS G12C mutant protein. KRASMutations of the KRAS gene are common in some non-small cell lung cancer (NSCLC), and effective treatments have been lacking for a long time. Sotorasiib blocks the active site of the mutated KRAS protein and inhibits signaling in cancer cells, thereby slowing down the growth and spread of tumors. This precise molecular targeting allows it to work only on cancer cells with specific mutations, while minimizing damage to normal cells.

Chemotherapy: Chemotherapy is a non-selective anti-cancer treatment in which drugs inhibit tumors by stopping rapidly dividing cells (such as cancer cells). While chemotherapy drugs block the division of cancer cells, they also affect other rapidly dividing cells in the body (such as blood cells, hair follicle cells, etc.). Therefore, the side effects of chemotherapy are broader and may have systemic effects throughout the body.

2. Differences in treatment effects

In terms of therapeutic effect, sotoracib is a targeted drug, mainly targeting patients with KRAS G12C mutation. Its efficacy is significantly better than traditional chemotherapy in such patients. Many clinical trials have shown that sotoraxib has a significant effect in delaying disease progression and reducing tumor size. In contrast, chemotherapy has a broad efficacy and is applicable to patients with many different types of cancer, but its effect in KRAS G12C mutated non-small cell lung cancer is relatively limited.

3. Differences in side effects

Side effects of targeted therapy: The side effects of sotoraxib are usually mild, mainly including fatigue, diarrhea, nausea, abnormal liver function, etc., and most side effects can be controlled through dose adjustment or auxiliary drugs. Because it is specific and selective for cancer cells, it has less impact on normal cells and has less impact on the patient's overall health.

Side effects of chemotherapy: Chemotherapy often causes serious and extensive side effects, including decreased immunity, hair loss, nausea, vomiting, fatigue, anemia, etc. These side effects occur because chemotherapy attacks all rapidly dividing cells, not just cancer cells but normal cells as well. Therefore, the quality of life of many chemotherapy patients will be greatly affected.

4. Achievement of personalized treatment

Sotorasiib, as a targeted drug, provides a more precise treatment option for patients withKRAS G12C mutation. This personalized treatment allows drugs to specifically target a patient's specific genetic mutations, thereby improving treatment effectiveness and reducing unnecessary side effects. Chemotherapy, on the other hand, does not have this level of precision, and its therapeutic effects are broad, but it is more limited in terms of personalization.

5. Indications and application scope

The scope of indications for sotoracib is relatively limited, and it is currently mainly targeted at patients with KRAS G12Cmutated non-small cell lung cancer. However, with the deepening of targeted drug research, more targeted drugs targeting different genetic mutations may become available in the future. Chemotherapy has a wider range of applications and is suitable for patients with various types of cancer, but it does not have a significant effect on all patients.

Sotoraxib targeted therapy and chemotherapy have their own advantages and disadvantages in the treatment of lung cancer. Targeted therapy is highly targeted, highly precise, and has fewer side effects, but its indications are limited. Chemotherapy has a wide range of applications, but has severe side effects and is not as accurate as targeted therapy. For lung cancer patients with KRAS G12C mutations, sotorasiib provides a more personalized treatment option, making the treatment effect more significant and the side effects relatively controllable.